MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · IEX Real-Time Price · USD
40.17
-1.24 (-2.99%)
At close: Jun 17, 2024, 4:00 PM
38.29
-1.88 (-4.68%)
Pre-market: Jun 18, 2024, 7:11 AM EDT
-2.99%
Market Cap 2.53B
Revenue (ttm) n/a
Net Income (ttm) -45.84M
Shares Out 62.87M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 197,816
Open 41.12
Previous Close 41.41
Day's Range 39.96 - 41.58
52-Week Range 25.13 - 64.98
Beta 1.25
Analysts Strong Buy
Price Target 75.00 (+86.71%)
Earnings Date May 7, 2024

About MLTX

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 50
Stock Exchange NASDAQ
Ticker Symbol MLTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for MLTX stock is "Strong Buy." The 12-month stock price forecast is $75.0, which is an increase of 86.71% from the latest price.

Price Target
$75.0
(86.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

4 weeks ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program...

6 weeks ago - GlobeNewsWire

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

2 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat...

2 months ago - Business Wire

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

3 months ago - GlobeNewsWire

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

3 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

3 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

4 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing t...

7 months ago - GlobeNewsWire

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis

8 months ago - GlobeNewsWire

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody ® sonelokimab as a highly promising and differentiated therapeutic solution for H...

8 months ago - GlobeNewsWire

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody ® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology C...

8 months ago - GlobeNewsWire

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody ® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatolog...

9 months ago - GlobeNewsWire

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

MoonLake Immunotherapeutics to ho st a Capital Markets Day on Monday , September 11

10 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

ZUG, Switzerland, August 10, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflamm...

11 months ago - GlobeNewsWire

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

MoonLake completes patient randomization ahead of         schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

11 months ago - GlobeNewsWire

Exclusive: MoonLake Immunotherapeutics explores sale-sources

MoonLake Immunotherapeutics , a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.

1 year ago - Reuters

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

MoonLake Immunotherapeutics Announces Pricin g of $ 40 0 Million Upsized Public Offering of Class A Ordinary Shares

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

MoonLake Immunot herapeutics achieves landmark milestone with positive Phase 2 results for Nanobody ® sonelokimab in hidradenitis suppurativa

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted the differentiating features of sonelokimab and st...

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, toda...

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases,...

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics com pletes patient enrol l ment and randomization ahead of schedule in a Phase 2 trial of the Nanobody ® sonelokimab in moderate-to-severe hidradenitis suppurativa

1 year ago - GlobeNewsWire